Treatment of Sjögren Syndrome with Cutaneous Vasculitis and Active Systemic Disease

Sjögren syndrome presenting with cutaneous vasculitis alongside active systemic disease represents a specific clinical scenario that requires a treatment approach matched to the degree of organ involvement and severity of the systemic picture.

Clinical scenario: Sjögren syndrome with concurrent cutaneous vasculitis and active systemic disease.

Treatment of systemic disease should be tailored to organ-specific severity. The strongest clinical indication for intervention in this setting relates to presentations linked to vasculitic involvement.

Treatment approach (partial overview): The evidence-based protocol for this scenario involves a glucocorticoid-based regimen, with the specific strategy differentiated according to whether the systemic presentation is moderate or severe. The full regimen — including sequencing, intensity thresholds, and all treatment options — is available via the structured protocol below.

Treatment goal: A reduction of ≥3 points in the global ESSDAI score is the recommended measure of therapeutic response in systemic Sjögren syndrome.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.
The best indication is probably for symptoms linked to cryoglobulinemic-associated vasculitis.
GCs should be used at the minimum dose and length of time necessary to control active systemic disease, administering pulses of methylprednisolone followed by doses of 0.5 mg/kg/d or lower as induction therapy in severe presentations, and doses <0.5 mg/kg/d in moderate/less-severe presentations, with a final target of withdrawing GCs in inactive patients as soon as possible or at least trying to target a maintenance dose of 5 mg/daily or less with the aid of GC-sparing immunosuppressive agents.
With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.

View source ↗